Outcomes of infliximab dose escalation in patients with rheumatoid arthritis.
Stanley B CohenJoel M KremerKimberly J DandreoGeorge W ReedRobert MagnerYing ShanShelly KafkaRaphael J DeHoratiusLorie EllisDennis ParentiPublished in: Clinical rheumatology (2019)
• Initial infliximab dose escalations (1 to 2) may be useful in lowering disease activity in patients with rheumatoid arthritis. • There does not appear to be a clinical benefit in infliximab dose escalations above the equivalent of 5 to 7 mg/kg.